is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus that causes coronavirus disease 2019 (COVID‑19).
COVID-19 vaccine candidates developed by a Sinopharm subsidiary and Sinovac Biotech to target the Omicron variant were approved for clinical trials in Hong Kong,...
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced study results in which opaganib, a leading oral drug candidate for hospitalized patients with moderate to...
Veru Inc., an oncology biopharmaceutical company, April 11th announced positive efficacy and safety results of Phase 3 COVID-19 clinical trial evaluating oral sabizabulin versus...
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), and GSK today announced that...
KeyPlants, a leading provider of innovative life science facilities and PODs, announced that it has shipped a first-of-its-kind vaccine manufacturing filling facility to Senegal...
TSB Therapeutics, the holding company of Brii Bio, and Sinopharm have entered into a strategic collaboration to commercialize Brii Bio's long-acting neutralizing monoclonal antibody...